BRIACELL THERAPEUTICS CORP. Net Income (Loss) Attributable to Noncontrolling Interest
BRIACELL THERAPEUTICS CORP. (BCTX) reported Net Income (Loss) Attributable to Noncontrolling Interest of -$72.55 thousand for the 3-month period ending 2026-04-30, per its 10-Q filed 2026-06-09.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2026-06-09
- BRIACELL THERAPEUTICS CORP. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-04-30 was -$72.55K.
- BRIACELL THERAPEUTICS CORP. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-01-31 was -$75.07K.
- BRIACELL THERAPEUTICS CORP. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-10-31 was -$80.76K.
- BRIACELL THERAPEUTICS CORP. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-07-31 was -$72.74K.
- BRIACELL THERAPEUTICS CORP. net income (loss) attributable to noncontrolling interest for fiscal 2025 was -$244.27K.
- BRIACELL THERAPEUTICS CORP. net income (loss) attributable to noncontrolling interest for fiscal 2024 was -$140.08K.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-04-30 | -$72.55K 10-Q · filed 2026-06-09 | -$147.62K derived: sum of 2 quarters · filed 2026-06-09 | -$228.38K 10-Q · filed 2026-06-09 | -$301.12K derived: sum of 4 quarters · filed 2026-06-09 |
| 2026-01-31 | -$75.07K 10-Q · filed 2026-03-10 | -$155.84K 10-Q · filed 2026-03-10 | -$228.57K derived: sum of 3 quarters · filed 2026-03-10 | -$326.60K derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-10-31 | -$80.76K 10-Q · filed 2025-12-11 | -$153.50K derived: sum of 2 quarters · filed 2025-12-11 | -$251.53K derived: sum of 3 quarters · filed 2026-06-09 | -$297.94K derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-07-31 | -$72.74K derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | -$170.76K derived: sum of 2 quarters · filed 2026-06-09 | -$217.17K derived: sum of 3 quarters · filed 2026-06-09 | -$244.27K 10-K · filed 2025-10-16 |
| 2025-04-30 | -$98.03K 10-Q · filed 2026-06-09 | -$144.44K derived: sum of 2 quarters · filed 2026-06-09 | -$171.54K 10-Q · filed 2026-06-09 | -$206.12K derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-01-31 | -$46.41K 10-Q · filed 2026-03-10 | -$73.51K 10-Q · filed 2026-03-10 | -$108.10K derived: sum of 3 quarters · filed 2026-03-10 | -$131.61K derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-10-31 | -$27.10K 10-Q · filed 2025-12-11 | -$61.69K derived: sum of 2 quarters · filed 2025-12-11 | -$85.20K derived: sum of 3 quarters · filed 2025-12-11 | -$124.51K derived: sum of 4 quarters · filed 2025-12-11 |
| 2024-07-31 | -$34.59K derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | -$58.10K derived: sum of 2 quarters · filed 2025-10-16 | -$97.41K derived: sum of 3 quarters · filed 2025-10-16 | -$140.08K 10-K · filed 2025-10-16 |
| 2024-04-30 | -$23.52K 10-Q · filed 2025-06-16 | -$62.82K derived: sum of 2 quarters · filed 2025-06-16 | -$105.50K 10-Q · filed 2025-06-16 | |
| 2024-01-31 | -$39.31K 10-Q · filed 2025-03-12 | -$81.98K 10-Q · filed 2025-03-12 | ||
| 2023-10-31 | -$42.67K 10-Q · filed 2024-12-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |